Sort
50,496 grants matching “lung cancer”
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
$1,000,000Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2022 · HL
Moffitt Cancer Center Support Grant
$1,000,000Thomas A Sellers · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2016 · CA
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)
$1,000,000Mallikarjun Srivatsan · Accurius Therapeutics, Inc. · R44 · FY2024 · CA
Precisely Shaped Acoustic Ablation of Tumors Under 3D Ultrasound Image Guidance
$1,000,000Everette C Burdette · Acoustic Medsystems, Inc. · R44 · FY2009 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2020 · CA
OTHER FUNCTIONS: TOPIC 287, PHASE II "NANOTECHNOLOGY SENSING PLATFORMS"
$1,000,000Swapnajit Chakravarty · Omega Optics, Inc. · N44 · FY2012 · CA
Tailored NRT Integrated with Smartphone Behavioral Support
$1,000,000Alan Joel Levy · Chrono Therapeutics, Inc. · R44 · FY2017 · CA
Leveraging Prospective Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk Scores
$1,000,000Fei Chen · University Of Southern California · U01 · FY2025 · CA
Rapid 3D Whole-Slide Digitization of Thick Cytopathology Slides with a Gigapixel Microscope
$1,000,000Mark Harfouche · Ramona Optics, Inc. · R44 · FY2022 · CA
Programmable Individualized NRT Merged With Digital Behavioral Support
$1,000,000Alan Joel Levy · Chrono Therapeutics, Inc. · R44 · FY2017 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA
SIRPant Technology for anti-Cancer Immunity
$999,999Nathanael McCurley · Bobcatbio, Inc. · R42 · FY2024 · CA
Expanding Vietnamese Community and Academic Infrastructure for Health Research
$999,998Bang H Nguyen · Cancer Prevention Instit Of California · RC4 · FY2010 · MD
Preclinical evaluation of a novel small molecule STAT inhibitor
$999,993Robert Sons · Fannin Partners, Llc · R44 · FY2018 · AI
There Will Be Blood: Stem Cell Niche Driven Derivation of HSC from ES Cells
$999,983Naoki Nakayama · University Of Texas Hlth Sci Ctr Houston · RC1 · FY2010 · HL
Improved diagnostic sensitivity for rapid COVID-19 testing using Enhanced Preservation Media
$999,975Trevor Levin · Convergent Genomics, Inc. · R44 · FY2020 · CA
DEVELOPMENT OF RESEARCH REAGENTS SPECIFIC FOR O-GLCNAC (O-GLCNAC LECTENZ)
$999,970Lori Yang · Lectenz Bio, Inc. · N44 · FY2013 · CA
A PROSPECTIVE STUDY OF ALASKA NATIVES &AMERICAN INDIANS
$999,952University Of Utah · R01 · FY2002 · CA
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II
$999,895Claude J. Rogers · Chromologic, Llc · R44 · FY2020 · AI
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II
$999,884Claude J. Rogers · Chromologic, Llc · R44 · FY2018 · AI
Point of Care Device for Antibody Independent Isolation of Circulating Tumor
$999,750Darren Davis · Apocell, Inc. · N44 · FY2013 · CA
Leveraging Diversity in Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk Scores
$999,722David V Conti · University Of Southern California · U01 · FY2021 · CA
Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer
$999,718Ramaswamy Govindan · Washington University · U01 · FY2024 · CA
Development of a lung cancer subtyping diagnostic
$999,637Harold R Garner · Orbit Genomics, Inc. · R44 · FY2025 · CA
OTHER FUNCTIONS CIRCULATING TUMOR CELL ENUMERATION PRODUCT
$999,613David Nelson · Epic Sciences, Inc. · N44 · FY2012 · CA